Stockreport

Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]

Taysha Gene Therapies, Inc.  (TSHA) 
PDF Received FDA clearance to initiate ASPIRE trial in three patients aged 2 to Maintained favorable tolerability profile with no treatment-related SAEs or DLTs in REVEA [Read more]